ClinicalTrials.gg

Program

HSK39004

A development code. Also written as “HSK39004 Inhalation Suspension”, “HSK39004 Dry Powder Inhaler-0.75mg” and “HSK39004 Dry Powder Inhaler -0.75mg BID”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Haisco Pharmaceutical Group.

Furthest: phase 3, since May 7, 20269 company-led studies, 7 open or runningNext primary completion: Jun 11, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group97 open or runningphase 3since May 7, 2026Dec 31, 2024Jun 11, 2027phase 3 · NCT07658339

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 31, 2024First study: phase 1 study in Healthy DonorsFirst studyNCT06905847 · 63 enrolled · China
  2. May 6, 2025Phase 1 study in Healthy VolunteersNCT06971198 · 26 enrolled · China
  3. Jul 31, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07108699 · 180 enrolled · China
  4. Aug 18, 20252 phase 2 studiesNCT07140328, NCT07331402
  5. Feb 13, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07425210 · 300 planned · China
  6. May 7, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructivePhase 3 reachedNCT07583849 · 376 planned · China
  7. Jun 3, 20262 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT07658339, NCT07634367

Ahead

  1. Jun 11, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07658339
  2. Jul 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07425210
  3. Sep 30, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07583849
  4. Dec 24, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07634367

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07658339Pulmonary Disease, Chronic Obstructive · China3Not yet recruitingJun 11, 2027387
NCT07634367Pulmonary Disease, Chronic Obstructive · China3Not yet recruitingDec 24, 2027300
NCT07583849Pulmonary Disease, Chronic Obstructive · China3RecruitingSep 30, 2027376
NCT07425210Pulmonary Disease, Chronic Obstructive · China2Not yet recruitingJul 2027300
NCT07331402COPD Patients · China2Active, not recruitingDec 30, 202512
NCT07140328Pulmonary Disease, Chronic Obstructive · China2RecruitingJul 10, 202550
NCT07108699Pulmonary Disease, Chronic Obstructive · China2Active, not recruitingAug 30, 2026180
NCT06971198Healthy Volunteers · China1CompletedMar 28, 202526
NCT06905847Healthy Donors · China1CompletedJan 13, 202563

How it is read

Names in the registry

  • “HSK39004 Inhalation Suspension”, 2 entries
  • “HSK39004 Dry Powder Inhaler-0.75mg”, 2 entries
  • “HSK39004 Dry Powder Inhaler -0.75mg BID”, 2 entries
  • “HSK39004 Dry Powder Inhaler -1.5mg BID”, 1 entry
  • “HSK39004 Inhalation Suspension -3mg BID”, 1 entry

Codes read as this program: HSK39004.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.